Y0000698

Paclitaxel

European Pharmacopoeia (EP) Reference Standard

• Fórmula empírica (notación de Hill): C₄₇H₅₁NO₁₄
• Número de CAS: 33069-62-4
• Peso molecular: 853.91
• Beilstein: 1420457
• Número MDL: MFCD00869953
• Código UNSPSC: 41116107
• ID de la sustancia en PubChem: 329831102
• NACRES: NA.24

Propiedades

• grado: pharmaceutical primary standard
• familia API: paclitaxel
• fabricante / nombre comercial: EDQM
• mp: 213 °C (dec.) (lit.)
• aplicaciones: pharmaceutical (small molecule)
• formato: neat
• temp. de almacenamiento: 2-8°C
• cadena SMILES: [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c5ccccc5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c6ccccc6)c7ccccc7
• InChI: 1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
• Clave InChI: RCINICONZNJXQF-MZXODVADSA-N
• Información sobre el gen: human ... TUBA1A(7846) , TUBA1B(10376) , TUBA1C(84790) , TUBA3C(7278) , TUBA3E(112714) , TUBA4A(7277) , TUBB(203068) , TUBB1(81027) , TUBB2A(7280) , TUBB2B(347733) , TUBB3(10381) , TUBB4A(10382) , TUBB4B(10383) , TUBB6(84617) , TUBB8(347688)

Descripción

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Paclitaxel EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Acciones bioquímicas o fisiológicas

Paclitaxel is a potent anti-neoplastic and anti-mitotic taxane drug, which binds to the N-terminus of β-tubulin and and stabilizes microtubules arresting the cell cycle at the G2/M phase. The microtubule damage induces apoptosis through a JNK-dependent pathway followed by a JNK-independent pathway, perhaps related to the activation of protein kinase A (PKA) or of Raf-1 kinase, resulting in phosphorylation of Bcl-2. A major metabolite via CYP2CB is 6α-hydroxypaclitaxel (6α-OHP).

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Precaución

Paclitaxel undergoes transesterification in methanol and hydrolyzes in aqueous solutions.

Otras notas

Sales restrictions may apply.

Información de seguridad

• Pictogramas: GHS08
• Palabra de señalización: Danger
• Frases de peligro: H341,H360FD,H372
• Consejos de prudencia: P202 - P260 - P264 - P280 - P308 + P313 - P405
• Clasificaciones de peligro: Muta. 2 - Repr. 1B - STOT RE 1
• Órganos de actuación: Central nervous system,Bone marrow,Cardio-vascular system
• Código de clase de almacenamiento: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Clase de riesgo para el agua (WGK): WGK 3
• Punto de inflamabilidad (°F): Not applicable
• Punto de inflamabilidad (°C): Not applicable